Trastuzumab versus observation for HER2 non amplified early breast cancer with Circulating Tumor Cells (EORTC90091-10093, BIG 1-12, Treat CTC): A randomized phase 2 trial - Ignatiadis, M; Litiere, S; Rothe, F (Ann Oncol, 2018)